89 Results for "

Cynomolgus monkey

" in MedChemExpress (MCE) Product Catalog:
Products (89)

89 Results for "Cynomolgus monkey" in MCE Product Catalog:

Cat. No.: HY-10294R
CAS No.: 362505-84-8
Synonyms: SB-462795 (Standard)
Research Areas:  

Metabolic Disease Cancer

Relacatib (Standard) is the analytical standard of Relacatib (HY-10294). This product is intended for research and analytical applications. Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .
loading...
    loading...
Cat. No.: HY-P991900

Target:  

CD19

Research Areas:  

Inflammation/Immunology

LY3541860 is a selective anti-CD19 antibody that both binds human CD19 with high affinity and selectively binds human B cells (Kd values: 76.8 pM and 94.5 nM for humans and cynomolgus monkeys, respectively). LY3541860 inhibits CpG-induced CD69 expression (IC50 = 0.006 nM). LY3541860 exhibits potent B cell inhibitory activities. LY3541860 can inhibit both BCR- and TLR-induced human B cell activation. LY3541860 can be used for the research of autoimmune diseases .
loading...
    loading...
Cat. No.: HY-P12211
Target:  

GLP Receptor

Research Areas:  

Others

GLP2 (rat) (11-33) is a glucagon-like peptide-2 receptor (GLP-2 receptor) antagonist. GLP2 (rat) (11-33) has weak intrinsic agonistic activity on human GLP-2R; it can synergistically enhance the activity of agonistic allosteric regulators on human, cynomolgus monkey, dog and Syrian hamster GLP-2R, but reduces this activity on rat GLP-2R. GLP2 (rat) (11-33) can be used for GLP-2R related research .
loading...
    loading...
Cat. No.: HY-P992381

Target:  

Drug Derivative

Research Areas:  

Cancer

IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (Kd = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .
loading...
    loading...
Cat. No.: HY-P992437

Target:  

CD44 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

PF-03475952 is a fully human IgG2 monoclonal antibody targeting CD44. PF-03475952 binds an epitope in CD44’s constant exons, blocks CD44-hyaluronic acid interaction, reduces cell surface CD44, and does not cross-react with rodent CD44 or LYVE-1. PF-03475952 induces cancer cell apoptosis, inhibits LPS (HY-D1056)-induced leukocyte cytokine release and cancer metastasis, and reduces CD44 expression on circulating CD3+ lymphocytes in cynomolgus monkeys. PF-03475952 can be used for the research of rheumatoid arthritis and hepatocellular carcinoma .
loading...
    loading...
Cat. No.: HY-189393
CAS No.: 3089177-97-6
Target:  

P-glycoprotein

Research Areas:  

Inflammation/Immunology

RTY-406 is an orally active ABCB4/MDR3 and ABCB11/BSEP positive modulator. RTY-406 increases ABCB4/MDR3 and ABCB11/BSEP protein levels and functional output, elevates biliary phospholipid levels, enhances bile acid efflux, increases bile flow and micelle formation, reduces hepatic bile acids, and promotes cholesterol-to-bile-acid conversion. RTY-406 does not induce hepatocellular injury, maintains normal serum alanine transaminase and aspartate aminotransferase levels, and shows a favorable safety profile in cynomolgus monkeys. RTY-406 can be used for the research of primary sclerosing cholangitis and cholestasis .
loading...
    loading...
Cat. No.: HY-P992448

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

RC98 is a monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) and acts as a selective PD-L1 inhibitor. RC98 binds specifically to human and cynomolgus monkey PD-L1. RC98 blocks the interaction between PD-L1 and its receptor PD-1 to reverse T-cell inactivation mediated by PD-1/PD-L1 signaling. RC98 enhances the cytotoxic T-lymphocyte-mediated anti-tumor immune response against PD-L1-expressing tumor cells. RC98 can be used for the research of tumor immunity and solid tumors .
loading...
    loading...
Cat. No.: HY-P992524
Target:  

CD3

Research Areas:  

Cancer

PF-07260437 is a bispecific monoclonal antibody targeting B7-H4 and CD3, with Kd values of 63.5 nM and 66.75 nM against human and cynomolgus monkey CD3, respectively. PF-07260437 simultaneously binds B7-H4 on tumor cells and the CD3ε subunit in the T cell receptor complex, forming a tumor cell-bispecific antibody-T cell trimer. This process establishes an immune synapse and initiates non-MHC-dependent T cell activation, proliferation, and release of cytotoxic molecules such as granzyme B to kill tumor cells. PF-07260437 can be used in research related to advanced or metastatic breast cancer, ovarian cancer, and endometrial cancer .
loading...
    loading...
Cat. No.: HY-P992024

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

SK48-E26 is a human interleukin-1β (IL-1β) inhibitor, with a IC50 of 400 pM against human IL-1β, a IC50 of 185 pM against cynomolgus monkey IL-1β, and a Ka value ranging from 0.048 nM to 3 nM for human IL-1β. SK48-E26 binds to the conformational epitope of human IL-1β spanning amino acid residues 95-101, and blocks the biological activity of IL-1β. SK48-E26 can be used in research related to IL-1β-mediated inflammatory diseases and osteoarthritis .
loading...
    loading...